Gounder, Mrinal M.
Agaram, Narasimhan P.
Trabucco, Sally E. http://orcid.org/0000-0002-8836-1542
Robinson, Victoria
Ferraro, Richard A. http://orcid.org/0000-0002-0660-2753
Millis, Sherri Z. http://orcid.org/0000-0002-5048-6841
Krishnan, Anita
Lee, Jessica
Attia, Steven
Abida, Wassim
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Chi, Ping
Angelo, Sandra P. D’ http://orcid.org/0000-0002-3736-3783
Dickson, Mark A.
Keohan, Mary Lou
Kelly, Ciara M. http://orcid.org/0000-0002-4393-8088
Agulnik, Mark
Chawla, Sant P.
Choy, Edwin http://orcid.org/0000-0001-9896-8084
Chugh, Rashmi
Meyer, Christian F.
Myer, Parvathi A.
Moore, Jessica L.
Okimoto, Ross A.
Pollock, Raphael E. http://orcid.org/0000-0002-0443-1583
Ravi, Vinod
Singh, Arun S.
Somaiah, Neeta http://orcid.org/0000-0002-0146-7732
Wagner, Andrew J.
Healey, John H. http://orcid.org/0000-0002-0802-1186
Frampton, Garrett M. http://orcid.org/0000-0002-2361-2750
Venstrom, Jeffrey M.
Ross, Jeffrey S. http://orcid.org/0000-0001-8494-2596
Ladanyi, Marc
Singer, Samuel
Brennan, Murray F. http://orcid.org/0000-0003-2358-4371
Schwartz, Gary K.
Lazar, Alexander J. http://orcid.org/0000-0002-6395-4499
Thomas, David M. http://orcid.org/0000-0002-2527-5428
Maki, Robert G. http://orcid.org/0000-0002-9853-2528
Tap, William D.
Ali, Siraj M.
Jin, Dexter X.
Article History
Received: 28 October 2021
Accepted: 4 May 2022
First Online: 15 June 2022
Competing interests
: M.M.G.: honoraria from Amgen, Bayer, Epizyme, Daiichi-Sankyo, Flatiron Therapeutics, Karyopharm, Medscape, PER, SpringWorks Therapeutics, Tracon, and UpToDate; D.X.J., S.E.T., J.L., G.M.F., J.M.V., S.Z.M.: employment by Foundation Medicine, Inc. and stock ownership in Roche; S.A.: research funding from AB Science, Adaptimmune, Advenchen Laboratories, Bavarian Nordic, Bayer, Blueprint Medicines, BTG Specialty Pharmaceuticals, CBA Pharma, Deciphera, Eli Lilly, Epizyme, Forma Therapeutics, Genmab, GlaxoSmithKline, Gradalis, Immune Design, Incyte, Karyopharm, Merck, Novartis, Philogen, PTC Therapeutics, SpringWorks Therapeutics, Takeda, TRACON Pharma; W.A.: research funding from AstraZeneca, Clovis Oncology, GlaxoSmithKline, Zenith Epigenetics; honoraria from Caret Pharma; consulting or advisory work for Clovis Oncology, Daiichi Sankyo, Janssen, MORE Health, and ORIC Pharmaceuticals; travel expenses from Clovis Oncology, GlaxoSmithKline, and ORIC Pharmaceuticals; A.D.: honoraria from or advisory work for Abbvie, ArcherDX, ARIAD Pharmaceuticals, AstraZeneca, Axis Therapeutics, Beigene, BergenBio, Blueprint Medicines, Elevation Oncology, Exelixis, Foundation Medicine, Genentech, Helsinn, Hengrui Therapeutics, Ignyta, Loxo Oncology, Medscape, Millennium Pharmaceuticals, MORE Health, OncLive, Paradigm Medical Communications, Peerview Institute, PeerVoice, Pfizer, Physicians Education Resources, Remedica Ltd., Research to Practice, Targeted Oncology, TP Therapeutics, Tyra Biosciences, Verastem, and WebMD; research funding from Exelixis, Foundation Medicine, GlaxoSmithKline, Pfizer, PharmaMar, Teva Pharmaceuticals, and Taiho; royalties from Wolters Kluwer; travel expenses from Boehringer Ingelheim, Merck, Merus, and Puma; P.C.: research funding from Array Biopharma and Novartis; advisory and consulting work for Deciphera and Exelixis; SPD: research funding from Amgen, Bristol-Myers Squibb, Deciphera, EMD Serono, Incyte, Merck, Nektar; consulting or advisory work for Amgen, GlaxoSmithKline, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer; travel expenses from Adaptimmune, EMD Serono, Immunocore, Merck; M.A.D.: research funding from Aadi Bioscience and Eli Lilly; C.F.M.: advisory work for Bayer and honoraria from Novartis; S.P.C.: research funding from Amgen, Ignyta, Immune Design, Karyopharm, Roche, Threshold Pharmaceuticals, and the Sarcoma Alliance for Research through Collaboration (SARC); E.C.: research funding from Adaptimmune, Amgen, AstraZeneca, Bayer, Exelixis, GlaxoSmithKline, Iterion Therapeutics, Merck, Mirati, and Novartis; A.J.W.: research funding from Aadi Bioscience, Daiichi-Sankyo, Eli Lilly, Karyopharm, Plexxikon; consulting for Daiichi-Sankyo, Deciphera, Nanocarrier; A.S.S.: research support from Blueprint Medicines, Deciphera, Eli Lilly, and Nanocarrier; consulting or speakers’ bureau fees from Certis Oncology, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Novartis, OncLive, and Roche; J.S.R.: employee of Foundation Medicine, Inc., board observer for Celsius Therapeutics, advisory work for Tango Therapeutics, stock ownership in the same 3 companies; D.M.T.: employee of Omico; research funding or support from Amgen, Astra Zeneca, Bayer, Eisai, Merck, Pfizer, and Roche; honoraria from Bayer, Merck, Pfizer, and Roche; RGM: research funding from Bayer, Eli Lilly, Karyopharm, Pfizer, Presage, Regeneron, SARC, SpringWorks Therapeutics; honoraria or consulting work for Bayer, Deciphera, Eisai, Epizyme, Foundation Medicine, GlaxoSmithKline, Imclone, Immune Design, Karyopharm, Novartis, Pfizer, PharmaMar, Presage, SARC, SpringWorks Therapeutics, UptoDate; W.D.T.: advisory board and consulting fees from Agios Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Immune Design, Janssen, and NanoCarrier; advisory board membership with stock interests for Atropos Therapeutics and Certis Oncology Solutions; pending patent through MSK for biomarkers of CDK4 inhibition; S.M.A.: employee of EQRx Inc. and advisor for Incysus Therapeutics and Elevation Oncology. All other authors have no relationships to disclose.